Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Ikano Bank AB (publ) in connection with the acquisition of a consumer credit unsecured loan portfolio from Nordnet Bank AB.
Mandate

Vinge has advised Ikano Bank AB (publ) in connection with the acquisition of a consumer credit unsecured loan portfolio from Nordnet Bank AB.

April 22, 2024 Banking and Finance Employment and Benefits M&A Financial Regulatory EU, Competition and Regulatory Corporate Tax Insurance Law

Vinge has advised Ikano Bank AB (publ) in connection with the acquisition of a consumer credit unsecured loan portfolio from Nordnet Bank AB. The final purchase price will be based on the outstanding loan volume in the portfolio as of closing date. As of March 2024, the outstanding loan volume in the portfolio amounted to approximately SEK 3.8 billion. The acquisition is subject to customary regulatory approvals.

Vinge's team consisted of Henrik Ossborn (Banking and Finance), Magnus Hedsund, Nicolas Ek, Irma Softic and Agaton Lindgren (M&A), Emelie Svensäter Jernstorp and Karin Hultgren (Employment), Henrik Schön and David Flodin (Financial Services), Sofie Nordgren and Nathalie Wikman (FDI), David Olander (Competition), Viveka Classon and David Gavatin (Corporate Insurance) and Ulf Nilsson (Tax).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026